XOMA Royalty (NASDAQ:XOMA) Rating Increased to Hold at TD Cowen

XOMA Royalty (NASDAQ:XOMA) was upgraded by analysts at TD Cowen to a “hold” rating in a note issued to investors on Friday,Zacks.com reports.

XOMA has been the topic of several other research reports. UBS Group set a $76.00 target price on shares of XOMA Royalty in a research report on Tuesday, December 9th. Stifel Nicolaus set a $50.00 price target on XOMA Royalty in a research report on Friday, December 12th. Zacks Research upgraded XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Monday, February 9th. Wall Street Zen cut XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. Three analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.60.

XOMA Royalty Stock Performance

Shares of XOMA stock opened at $24.01 on Friday. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91. The firm has a 50-day moving average of $26.44 and a 200-day moving average of $31.08. XOMA Royalty has a one year low of $18.35 and a one year high of $39.92. The company has a market cap of $297.24 million, a P/E ratio of 32.45 and a beta of 0.86.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a return on equity of 2.91% and a net margin of 32.28%.The firm had revenue of $9.35 million for the quarter, compared to analysts’ expectations of $11.47 million. Equities research analysts forecast that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Owen Hughes bought 100,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was acquired at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the transaction, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. This represents a 5,000.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 9.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. State Street Corp increased its position in shares of XOMA Royalty by 4.7% during the fourth quarter. State Street Corp now owns 174,908 shares of the biotechnology company’s stock valued at $4,651,000 after buying an additional 7,873 shares during the period. Wells Fargo & Company MN grew its stake in XOMA Royalty by 66.0% during the fourth quarter. Wells Fargo & Company MN now owns 10,755 shares of the biotechnology company’s stock valued at $286,000 after acquiring an additional 4,278 shares in the last quarter. Renaissance Technologies LLC increased its holdings in XOMA Royalty by 35.0% during the 4th quarter. Renaissance Technologies LLC now owns 39,017 shares of the biotechnology company’s stock worth $1,037,000 after acquiring an additional 10,117 shares during the period. Dimensional Fund Advisors LP lifted its stake in XOMA Royalty by 48.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 43,335 shares of the biotechnology company’s stock worth $1,152,000 after purchasing an additional 14,145 shares in the last quarter. Finally, Los Angeles Capital Management LLC boosted its holdings in XOMA Royalty by 31.7% in the 4th quarter. Los Angeles Capital Management LLC now owns 19,332 shares of the biotechnology company’s stock valued at $514,000 after purchasing an additional 4,656 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.